BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 3.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 2,077,966 shares of the biotechnology company’s stock after selling 71,003 shares during the period. Jupiter Asset Management Ltd.’s holdings in BioCryst Pharmaceuticals were worth $18,619,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Allianz Asset Management GmbH lifted its holdings in BioCryst Pharmaceuticals by 9.6% in the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 1,200 shares during the last quarter. Royal Bank of Canada raised its position in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. Wellington Management Group LLP lifted its holdings in shares of BioCryst Pharmaceuticals by 2.6% in the 1st quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock worth $685,000 after purchasing an additional 2,291 shares during the last quarter. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter valued at approximately $32,000. Finally, R Squared Ltd boosted its position in BioCryst Pharmaceuticals by 84.2% during the 1st quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 5,335 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 0.7%

BioCryst Pharmaceuticals stock opened at $7.18 on Thursday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.31. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -39.89 and a beta of 1.09. The company’s 50-day moving average price is $7.38 and its two-hundred day moving average price is $8.65.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. During the same period in the previous year, the business earned ($0.07) EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 36.1% on a year-over-year basis. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BCRX. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Needham & Company LLC cut their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Barclays decreased their target price on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th. TD Cowen began coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.33.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.